Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis—EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol
Gordon W Moran, Shellie J Radford, Alissa Walsh, Robert Battat, Michael McLean, Maria Kudela, Elke Binder, Nataliia Kulchytska, Burak Sahin, Ulf Helwig, Peter M Irving · 2025
Read Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis—EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol by Gordon W Moran, Shellie J Radford, Alissa Walsh, Robert Battat, Michael McLean, Maria Kudela, Elke Binder, Nataliia Kulchytska, Burak Sahin, Ulf Helwig, Peter M Irving (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742082.txt.
Description
Gordon Moran and co-authors set out the plan for EFFECT-UC, a real-world study of a daily pill for ulcerative colitis, in a 2025 protocol paper. The pill, etrasimod, calms the immune system and already proved itself in strict trials for people with moderately to severely active disease. What trials cannot show is how the drug performs in everyday clinics, where patients and care vary much more.
The study will follow adults in several countries for 52 weeks of treatment plus a short safety check afterward, aiming for about 300 patients in each group. Doctors choose the treatment as they normally would. Patients report their symptoms on electronic forms, daily at first and then at set visits, and some give stool samples or have bowel imaging. The main questions are how many reach symptom remission by week 12 and week 52, and how many stay free of steroids.
Catalog record
| CREATOR | Gordon W Moran, Shellie J Radford, Alissa Walsh, Robert Battat, Michael McLean, Maria Kudela, Elke Binder, Nataliia Kulchytska, Burak Sahin, Ulf Helwig, Peter M Irving |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |